Nurse Practitioner Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Kim Huynh

Nurse Practitioner, Acute Care Cypress, TX Nurse Practitioner

NPI 1104396647 CMS profile 5697120

27800 Northwest Fwy Ste 4201, Cypress, TX 77433

Open in the dashboard

General payments

$28,842

658 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kim Huynh of Cypress, TX is reported in the CMS Open Payments database as having received $28,842 across 658 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2024 General $46 2
2023 General $70 4
2022 General $16,870 237
2021 General $11,703 408
2020 General $126 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kim Huynh
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Kim Huynh were reported at $28. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Kim Huynh Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $126 — — $114
2021 $11,703 $123 $38–$327 $132
2022 $16,870 $130 $44–$369 $149
2023 $70 $144 $49–$410 $160
2024 $46 $146 $48–$433 $164
2025 $28 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. GRT US Holding, Inc. $16,836 71 payments
  2. AbbVie, Inc. $1,504 107 payments
  3. Biogen, Inc. $1,023 35 payments
  4. Biohaven Pharmaceuticals, Inc. $877 42 payments
  5. Genzyme Corporation $834 23 payments
  6. Novartis Pharmaceuticals Corporation $698 50 payments
  7. Teva Pharmaceuticals USA, Inc. $692 28 payments
  8. Allergan Inc. $624 36 payments
  9. Lilly USA, LLC $496 30 payments
  10. UCB, Inc. $484 18 payments
  11. Other $4,774 218 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $13,547 635 payments
  2. Honoraria $9,600 6 payments
  3. Consulting Fee $3,500 1 payment
  4. Travel and Lodging $2,097 12 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $98 4 payments
Products named General payments · program years 2020–2025
  1. Qutenza $16,836 71 payments
  2. NURTEC ODT $1,069 53 payments
  3. UBRELVY $714 46 payments
  4. BOTOX $639 37 payments
  5. KESIMPTA $621 45 payments
  6. EMGALITY $496 30 payments
  7. REYVOW $496 30 payments
  8. AIMOVIG $480 21 payments
  9. AUBAGIO $473 19 payments
  10. VUMERITY $434 20 payments
  11. Other $6,999 334 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

60

Median for Nurse Practitioner: 389

Drug cost

$442

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cefdinir Generic 20 $277
Pantoprazole Sodium Generic 16 $107
Potassium Chloride Generic 11 $33
Prednisone Generic 13 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
  • ACADIA Pharmaceuticals Inc $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

658 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record